Physician profile
Michael D Becker
NPI 1538115787
$546.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.56 · 2020: $50.28 · 2021: $406 · 2022: $13.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $99.99 | 2020-2021 | |
| Novo Nordisk INC | $84.70 | 2019-2021 | |
| Pfizer INC. | $83.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $43.12 | 2021-2022 | |
| Amgen INC. | $39.16 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.30 | 2021 | |
| Lilly USA, LLC | $27.74 | 2021 | |
| Abbvie INC. | $26.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2021 | |
| Esperion Therapeutics, INC. | $22.29 | 2021 | |
| Si-Bone, INC. | $19.25 | 2021 | |
| Hologic Sales and Service, LLC | $16.45 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.85 | 2021 | |
| Boston Scientific Corporation | $14.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.